GSK Requip Restless Legs Syndrome sNDA On Track For 2003
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
GlaxoSmithKline plans to file an sNDA this year for its Parkinson’s disease therapy Requip (ropinirole) in the treatment of restless legs syndrome.